Anorexia Nervosa
Anorexia Nervosa (AN) is an eating disorder marked by weight loss (or a lack of proper weight gain in growing children), difficulty maintaining a healthy body weight for one's height, age, and stature, and, in many cases, a distorted body image. Anorexics typically limit their calorie intake and the sorts of foods they consume.
The exact cause of anorexia nervosa remains unknown. Genetic risk factors and a combination of environmental, social, and cultural factors may all play a role. It's conceivable that certain personality qualities make some people more sensitive to anorexia than others.
Anorexia Nervosa Epidemiology Segmentation in the 7MM
- Prevalent Cases of Anorexia Nervosa
- Diagnosed Prevalent Cases of Anorexia Nervosa
- Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa
Anorexia Nervosa Epidemiological Insights Observed in the 7MM (2021)
- The total incident cases of Anorexia Nervosa observed in the 7MM were observed to be 1.6 Million in the year 2021
Anorexia Nervosa Market Insight
The market size of Anorexia Nervosa in the 7MM was approximately USD 63 Million in 2021.
Anorexia Nervosa Market Strengths
The increasing prevalent population and increasing episodes of Anorexia Nervosa worldwide are likely to cause a surge in treatment options. Consequently, the market will witness a boost in the upcoming year.
Anorexia Nervosa Market Opportunities
As most of the guidelines recommend to use of drug therapy along with psychotherapies, the drug developer company can come up with innovative treatment packs that include drug plus psychotherapy.
Anorexia Nervosa Emerging Drugs
- The emerging drugs in the Anorexia Nervosa market are
- Psilocybin
- Ketamine, and others
Anorexia Nervosa Key Players
The key players working in the Anorexia Nervosa market are
- Homeostasis Therapeutics, LLC
- COMPASS Pathways, and others